Becton, Dickinson and Company (NYSE:BDX) Issues FY 2026 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 12.620-12.720 for the period, compared to the consensus earnings per share estimate of 12.560. The company issued revenue guidance of -.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded down $0.65 on Friday, hitting $176.42. The stock had a trading volume of 287,361 shares, compared to its average volume of 2,705,098. The firm’s 50 day moving average price is $153.78 and its 200-day moving average price is $162.41. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The company has a market capitalization of $48.61 billion, a price-to-earnings ratio of 44.68, a price-to-earnings-growth ratio of 12.16 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period in the previous year, the business earned $3.68 earnings per share. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 12.53 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

Analysts Set New Price Targets

Several research firms have weighed in on BDX. Royal Bank Of Canada restated a “sector perform” rating on shares of Becton, Dickinson and Company in a research report on Friday. Barclays raised their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Piper Sandler decreased their price objective on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Finally, TD Cowen upped their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $184.13.

Insiders Place Their Bets

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. The trade was a 2.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 5,189 shares of company stock worth $765,661. 0.40% of the stock is currently owned by company insiders.

More Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported fiscal Q3 revenue of approximately $5.0 billion, up 5.4% year over year, exceeding the roughly $4.89 billion consensus estimate. Adjusted diluted EPS of $3.23 also topped expectations of $3.14. BD Reports Third Quarter Fiscal 2026 Financial Results
• Positive Sentiment: Management raised fiscal 2026 adjusted EPS guidance to $12.62-$12.72, above the $12.56 analyst consensus, and expects revenue growth toward the high end of its prior range. Becton Dickinson Signals Strong Growth Momentum By Raising Profit Outlook
• Positive Sentiment: BD highlighted growth across its core Medical and Interventional businesses. Year-to-date cash flow from continuing operations rose 33.3% to $2.1 billion, while free cash flow increased 44.6% to $1.7 billion, improving financial flexibility. Becton, Dickinson Fiscal Q3 Adjusted Earnings, Revenue Rise; Lifts 2026 Adjusted EPS Guidance
• Neutral Sentiment: The earnings beat was partly offset by profitability pressure: gross and operating margins declined, and adjusted EPS fell from $3.68 a year earlier despite revenue growth. Investors may focus on whether BD can convert sales momentum into sustained margin expansion. BD Stock Up in Pre-Market Post Q3 Earnings & Revenue Beat, Margins Down
• Negative Sentiment: BD recently recalled needles used in a vascular access system following reports involving four patient deaths. The recall could create regulatory, legal and reputational concerns, although the earnings reports did not quantify a financial impact. BD Recalls Vascular Access System Needles After Four Patient Deaths

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Cambient Family Office LLC bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at approximately $217,000. Compound Planning Inc. lifted its stake in Becton, Dickinson and Company by 72.9% in the 4th quarter. Compound Planning Inc. now owns 2,887 shares of the medical instruments supplier’s stock valued at $560,000 after purchasing an additional 1,217 shares during the last quarter. Invesco Ltd. boosted its position in Becton, Dickinson and Company by 48.5% in the fourth quarter. Invesco Ltd. now owns 3,790,490 shares of the medical instruments supplier’s stock valued at $735,620,000 after buying an additional 1,237,507 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its stake in shares of Becton, Dickinson and Company by 22.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 28,140 shares of the medical instruments supplier’s stock worth $5,461,000 after buying an additional 5,106 shares during the last quarter. Finally, Andrews Advisory Associates LLC acquired a new position in Becton, Dickinson and Company in the 4th quarter worth about $253,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.